Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck Serono, a division of Merck KGaA, has reported that Glucophage powder for oral solution in sachets, indicated for the first-line treatment of type 2 diabetes mellitus, is now licensed in France and the UK, the first European countries to launch this new formulation of Glucophage.
Subscribe to our email newsletter
According to Merck, launches in other European countries are expected to take place in the coming months, once individual marketing authorizations are granted.
Bioequivalent to the existing Glucophage tablets, the new powder formulation is packaged in individual sachets of 500mg, 850mg and 1,000mg.
Roberto Gradnik, executive vice president of commercial Europe at Merck Serono, said: “Adherence to therapy is increasingly being recognized by physicians as a key condition to achieve glycemic control for patients with diabetes. We are pleased to provide this innovative powder formulation of Glucophage to patients seeking a convenient alternative to tablets which may facilitate their adherence to treatment.”